GlassScriptPhysician profile
Richard P Bose
NPI 1689739021
$4,491.14
in general payments reported to CMS, 2019-2025
32 companies · $23.39 in 2025
The $23.39 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,997 · 2020: $511 · 2021: $655 · 2022: $755 · 2023: $387 · 2024: $162 · 2025: $23.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $572.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,878.70 | 2019-2024 | Eterna, Proclaim |
| Medtronic, INC. | $513.94 | 2021-2023 | Vanta Adaptivestim, Synchromedii, Intellis Adaptivestim |
| Amgen INC. | $291.05 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $235.33 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $153.54 | 2019-2021 | |
| Lilly USA, LLC | $153.49 | 2019 | |
| Medtronic USA, INC. | $151.88 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $129.37 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $111.54 | 2019-2020 | |
| Boston Scientific Corporation | $99.28 | 2019-2020 | |
| Pfizer INC. | $73.57 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $68.61 | 2020-2023 | Ajovy |
| Abbvie INC. | $66.78 | 2022-2023 | Botox |
| Pacira Therapeutics, INC. | $63.68 | 2019-2020 | |
| Vertos Medical, INC. | $63.58 | 2023 | Mild Device Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $49.46 | 2021 | |
| Forte Bio-Pharma LLC | $48.11 | 2023 | Prolate, Nalocet |
| Tersera Therapeutics LLC | $38.93 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.31 | 2019-2020 | |
| Nalu Medical, INC. | $32.60 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.49 | 2022 | |
| Spr Therapeutics, INC | $28.00 | 2022 | |
| Tactile Systems Technology INC | $25.73 | 2024 | Entre Plus, Flexitouch Plus |
| Merck Sharp & Dohme LLC | $23.39 | 2025 | Bridion |
| Kowa Pharmaceuticals America, INC. | $20.35 | 2023 | Seglentis |
| Indivior INC. | $18.43 | 2020 | |
| Averitas Pharma INC. | $17.68 | 2023 | Qutenza |
| Eisai INC. | $15.04 | 2020 | |
| Allergan, INC. | $13.75 | 2019 | |
| Kaleo, INC. | $12.70 | 2019 | |
| Sentynl Therapeutics, INC. | $12.44 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Bose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.